- Fletcher, C.D.M. et al. Pathology and Genetics of Tumours of Soft Tissue and Bone/C.D.M.
Fletcher, J.A. Bridge, J.A. Hogendoorn//WHO classification 2013. - 5.
- Doyle, L.A. Sarcoma classification: An update based on the 2013 World health organization classification of tumors of soft tissue and bone/L.A. Doyle//Cancer. - 2014. - 120. - P. 1763 - 1774.
- Ritter, J. et al. Osteosarcoma. Annals of Oncology/J. Ritter, S.S. Bielack//2010. - 21. - P. 320 - 325.
- Sobin, L.H. et al. TNM classification of malignant tumours/L.H. Sobin, M.K. Gospodarowicz//2009. - P. 153 - 156.
- EURAMOS1: A randomized trial of the European and American Osteosarcoma Study Group
to optimize treatment strategies for resectable osteosarcoma based on histological response to preoperative chemotherapy. http://www.ctu.mrc.ac.uk/euramos
- Bacci, G. et al. Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report/G. Bacci, S. Ferrari, F. Bertoni//Journal of clinical oncology. - 2000. - 18. - 24. - P. 4016 - 4027.
- Ferrari, S. et al. Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1/S. Ferrari, P. Ruqqieri, G. Cefalo//Journal of clinical oncology. - 2012. - 30. - 17. - P. 2112 - 2118.
- Ferrari, S. et al. Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups/S. Ferrari, S. Smeland, M. Mercuri//Journal of clinical oncology. - 2005. - 23. - 34. - P. 8845 - 8852.
- Hegyi, M. et al. Good Prognosis of Localized Osteosarcoma in Young Patients Treated With Limb-Salvage Surgery and Chemotherapy/M. Hegyi, A.F. Semsei, Z. Jakab//Pediatric Blood Cancer. - 2011. - 57. - P. 415 - 422.
- Smeland, S. et al. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma/S. Smeland, O.S. Bruland, L. Hjorth//Acta Orthopaedica. - 2011. - 82. - 2. - P. 211 - 216.
- Iwamoto, Y. et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J/Y. Iwamoto, K. Tanaka, K. Isu//Journal of orthopedic science. - 2009. - 14. - P. 397 - 404.
- Petrilli, S. et al. Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: Prognostic Factors and Impact on Survival/S. Petrilli, B. de Camargo, V.O. Filho//Journal of clinical oncology. - 2006. - 24. - 7. - P. 1161 - 1168.
- Goorin, A.M. et al. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651/A.M. Goorin, D.J. Shwartzentruber, M. Devidas//Journal of clinical oncology. - 2003.
- 21. - P. 1574 - 1580.
- Le Deley, M.C. et al. SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients/M.C. Le Deley, J.M. Guinebretiere, V.C. Gentet//European journal of cancer. - 2007. - 43. - P. 752 - 761.
- Hinds, P.S. et al. Aggressive treatment of non-metastatic osteosarcoma improves health- related quality of life in children and adolescents/P.S. Hinds, J.S. Gattuso, C.A. Billups//European journal of cancer. - 2009. - 45. - P. 2007 - 2014.
- Daw, N.C. et al. Frontline Treatment of Localized Osteosarcoma Without Methotrexate/N.C. Daw, M.D. Neel, B.N. Rao//Cancer. - 2011. - 117. - P. 2770 - 2778.
- Meyers, P.A. et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group/P.A. Meyers, C.L. Schwartz, M.D. Krailo//Journal of clinical oncology. - 2008. - 28. - 9. - P. 633 - 638.
- Meyers, P.A. et al. Addition of pamidronate to chemotherapy for the treatment of
osteosarcoma/P.A. Meyers, J.H. Healeya, A.J. Choua//Cancer. - 2011. - 117. - 8. - P. 1736 - 1744.
- Isakoff, M.S. et al. Poor Survival for Osteosarcoma of the Pelvis: A Report from the Children's Oncology Group/M.S. Isakoff, D.A. Barkauskas, D. Ebb//Clinical Orthopedics Related Research. - 2012. - 470. - P. 2007 - 2013.
- Boye, K. et al. High-Dose Chemotherapy with Stem Cell Rescue in the Primary Treatment of Metastatic and Pelvic Osteosarcoma: Final Results of the ISG/SSG II Study/K. Boye, A.B. Del Prever, E. Eiksson//Pediatric blood cancer. - 2014. - 61. - 5. - P. 840 - 845.
- Smeland, S. Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1/S. Smeland, J. Whelan, S.S. Bielack//Journal of clinical oncology. - 2015. - 33 (suppl; abstr 10512). - http://meetinglibrary.asco.org/content/143782-156 (http://meetinglibrary.asco.org/).
- Whelan, J.S. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment/J.S. Whelan, S.S. Bielack, N. Marina//Annals of oncology. - 2015. - 26. - P. 407 - 414. (http://meetinglibrary.asco.org/).
- Daw, N.C. et al. Metastatic Osteosarcoma. Results of Two Consecutive Therapeutic Trials at St. Jude Children's Research Hospital/N.C. Daw, C.A. Billups, C. Rodriques- Galindo//Cancer. - 2006. -106. - P. 403-12. (http://meetinglibrary.asco.org/).
- Ebb, D. et al. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group/D. Ebb, G. Holcombe, M. Karen//Journal of clinical oncology. - 2012. - 30. - 20. - P. 2245 - 2551. (http://meetinglibrary.asco.org/).
- Goldsby, R.E. et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent hemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group/R.E. Goldsby, T.M. Fan, D. Vallaluna//European Journal of Cancer. - 2013. - 49. - P. 2384 - 2391. (http://meetinglibrary.asco.org/).
- Lee, J.A. at al. Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy/J.A. Lee, D.G. Jeon,